Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 522

1.

Serious Altitude Illness at the South Pole.

Rose JS, Law J, Scheuring R, Ramage MH, McKeith JJ.

Aerosp Med Hum Perform. 2020 Jan 1;91(1):46-50. doi: 10.3357/AMHP.5467.2020.

PMID:
31852574
2.

Interleukin-6 plays a critical role in aldosterone-induced macrophage recruitment and infiltration in the myocardium.

Liao CW, Chou CH, Wu XM, Chen ZW, Chen YH, Chang YY, Wu VC, Rose-John S, Hung CS, Lin YH; TAIPAI Study Group.

Biochim Biophys Acta Mol Basis Dis. 2020 Mar 1;1866(3):165627. doi: 10.1016/j.bbadis.2019.165627. Epub 2019 Nov 28.

PMID:
31785407
3.

ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer.

Schumacher N, Rose-John S.

Cancers (Basel). 2019 Nov 5;11(11). pii: E1736. doi: 10.3390/cancers11111736. Review.

4.

STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis.

Heichler C, Scheibe K, Schmied A, Geppert CI, Schmid B, Wirtz S, Thoma OM, Kramer V, Waldner MJ, Büttner C, Farin HF, Pešić M, Knieling F, Merkel S, Grüneboom A, Gunzer M, Grützmann R, Rose-John S, Koralov SB, Kollias G, Vieth M, Hartmann A, Greten FR, Neurath MF, Neufert C.

Gut. 2019 Nov 4. pii: gutjnl-2019-319200. doi: 10.1136/gutjnl-2019-319200. [Epub ahead of print]

PMID:
31685519
5.

Regulation of Fibrotic Processes in the Liver by ADAM Proteases.

Schmidt-Arras D, Rose-John S.

Cells. 2019 Oct 9;8(10). pii: E1226. doi: 10.3390/cells8101226. Review.

6.

IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling.

Wilkinson AN, Chang K, Kuns RD, Henden AS, Minnie SA, Ensbey KS, Clouston AD, Zhang P, Koyama M, Hidalgo J, Rose-John S, Varelias A, Vuckovic S, Gartlan KH, Hill GR.

Blood. 2019 Dec 5;134(23):2092-2106. doi: 10.1182/blood.2019000396.

PMID:
31578204
7.

Treatment of type 2 diabetes with the designer cytokine IC7Fc.

Findeisen M, Allen TL, Henstridge DC, Kammoun H, Brandon AE, Baggio LL, Watt KI, Pal M, Cron L, Estevez E, Yang C, Kowalski GM, O'Reilly L, Egan C, Sun E, Thai LM, Krippner G, Adams TE, Lee RS, Grötzinger J, Garbers C, Risis S, Kraakman MJ, Mellet NA, Sligar J, Kimber ET, Young RL, Cowley MA, Bruce CR, Meikle PJ, Baldock PA, Gregorevic P, Biden TJ, Cooney GJ, Keating DJ, Drucker DJ, Rose-John S, Febbraio MA.

Nature. 2019 Oct;574(7776):63-68. doi: 10.1038/s41586-019-1601-9. Epub 2019 Sep 25.

PMID:
31554967
8.

ADAM17: An Emerging Therapeutic Target for Lung Cancer.

Saad MI, Rose-John S, Jenkins BJ.

Cancers (Basel). 2019 Aug 21;11(9). pii: E1218. doi: 10.3390/cancers11091218. Review.

9.

IL-6 trans-signaling in the brain influences the behavioral and physio-pathological phenotype of the Tg2576 and 3xTgAD mouse models of Alzheimer's disease.

Escrig A, Canal C, Sanchis P, Fernández-Gayol O, Montilla A, Comes G, Molinero A, Giralt M, Giménez-Llort L, Becker-Pauly C, Rose-John S, Hidalgo J.

Brain Behav Immun. 2019 Nov;82:145-159. doi: 10.1016/j.bbi.2019.08.005. Epub 2019 Aug 8.

PMID:
31401302
10.

The Synthetic Retinoid Acitretin Increases IL-6 in the Central Nervous System of Alzheimer Disease Model Mice and Human Patients.

Dos Santos Guilherme M, Stoye NM, Rose-John S, Garbers C, Fellgiebel A, Endres K.

Front Aging Neurosci. 2019 Jul 23;11:182. doi: 10.3389/fnagi.2019.00182. eCollection 2019.

11.

Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma.

Scherger AK, Al-Maarri M, Maurer HC, Schick M, Maurer S, Öllinger R, Gonzalez-Menendez I, Martella M, Thaler M, Pechloff K, Steiger K, Sander S, Ruland J, Rad R, Quintanilla-Martinez L, Wunderlich FT, Rose-John S, Keller U.

JCI Insight. 2019 Aug 8;4(15). pii: 128435. doi: 10.1172/jci.insight.128435. eCollection 2019 Aug 8.

12.

Meprin β induces activities of A disintegrin and metalloproteinases 9, 10, and 17 by specific prodomain cleavage.

Wichert R, Scharfenberg F, Colmorgen C, Koudelka T, Schwarz J, Wetzel S, Potempa B, Potempa J, Bartsch JW, Sagi I, Tholey A, Saftig P, Rose-John S, Becker-Pauly C.

FASEB J. 2019 Nov;33(11):11925-11940. doi: 10.1096/fj.201801371R. Epub 2019 Aug 9.

PMID:
31381863
13.

Differences in Shedding of the Interleukin-11 Receptor by the Proteases ADAM9, ADAM10, ADAM17, Meprin α, Meprin β and MT1-MMP.

Sammel M, Peters F, Lokau J, Scharfenberg F, Werny L, Linder S, Garbers C, Rose-John S, Becker-Pauly C.

Int J Mol Sci. 2019 Jul 26;20(15). pii: E3677. doi: 10.3390/ijms20153677.

14.

Interleukin 6 Dependent Synaptic Plasticity in a Social Defeat-Susceptible Prefrontal Cortex Circuit.

Esquivel-Rendón E, Vargas-Mireles J, Cuevas-Olguín R, Miranda-Morales M, Acosta-Mares P, García-Oscos F, Pineda JC, Salgado H, Rose-John S, Atzori M.

Neuroscience. 2019 Aug 21;414:280-296. doi: 10.1016/j.neuroscience.2019.07.002. Epub 2019 Jul 10.

PMID:
31301368
15.

The ADAM17 Protease Promotes Tobacco Smoke Carcinogen-induced Lung Tumourigenesis.

Saad MI, McLeod L, Yu L, Ebi H, Ruwanpura S, Sagi I, Rose-John S, Jenkins BJ.

Carcinogenesis. 2019 Jun 27. pii: bgz123. doi: 10.1093/carcin/bgz123. [Epub ahead of print]

PMID:
31257400
16.

The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes.

Aparicio-Siegmund S, Garbers Y, Flynn CM, Waetzig GH, Gouni-Berthold I, Krone W, Berthold HK, Laudes M, Rose-John S, Garbers C.

Am J Physiol Endocrinol Metab. 2019 Aug 1;317(2):E411-E420. doi: 10.1152/ajpendo.00166.2019. Epub 2019 Jun 25.

PMID:
31237452
17.

Degradome of soluble ADAM10 and ADAM17 metalloproteases.

Scharfenberg F, Helbig A, Sammel M, Benzel J, Schlomann U, Peters F, Wichert R, Bettendorff M, Schmidt-Arras D, Rose-John S, Moali C, Lichtenthaler SF, Pietrzik CU, Bartsch JW, Tholey A, Becker-Pauly C.

Cell Mol Life Sci. 2020 Jan;77(2):331-350. doi: 10.1007/s00018-019-03184-4. Epub 2019 Jun 17.

PMID:
31209506
18.

Functional Characterization of Colon Cancer-Associated Mutations in ADAM17: Modifications in the Pro-Domain Interfere with Trafficking and Maturation.

Pavlenko E, Cabron AS, Arnold P, Dobert JP, Rose-John S, Zunke F.

Int J Mol Sci. 2019 May 4;20(9). pii: E2198. doi: 10.3390/ijms20092198. Review.

19.

Modulation of the IL-6-Signaling Pathway in Liver Cells by miRNAs Targeting gp130, JAK1, and/or STAT3.

Servais FA, Kirchmeyer M, Hamdorf M, Minoungou NWE, Rose-John S, Kreis S, Haan C, Behrmann I.

Mol Ther Nucleic Acids. 2019 Jun 7;16:419-433. doi: 10.1016/j.omtn.2019.03.007. Epub 2019 Apr 2.

20.

ADAM17-deficiency on microglia but not on macrophages promotes phagocytosis and functional recovery after spinal cord injury.

Sommer D, Corstjens I, Sanchez S, Dooley D, Lemmens S, Van Broeckhoven J, Bogie J, Vanmierlo T, Vidal PM, Rose-John S, Gou-Fabregas M, Hendrix S.

Brain Behav Immun. 2019 Aug;80:129-145. doi: 10.1016/j.bbi.2019.02.032. Epub 2019 Mar 6.

21.

ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.

Saad MI, Alhayyani S, McLeod L, Yu L, Alanazi M, Deswaerte V, Tang K, Jarde T, Smith JA, Prodanovic Z, Tate MD, Balic JJ, Watkins DN, Cain JE, Bozinovski S, Algar E, Kohmoto T, Ebi H, Ferlin W, Garbers C, Ruwanpura S, Sagi I, Rose-John S, Jenkins BJ.

EMBO Mol Med. 2019 Apr;11(4). pii: e9976. doi: 10.15252/emmm.201809976.

22.

Correction to: A new multiple trauma model of the mouse.

Fitschen-Oestern S, Lippross S, Klueter T, Weuster M, Varoga D, Tohidnezhad M, Pufe T, Rose-John S, Andruszkow H, Hildebrand F, Steubesand N, Seekamp A, Neunaber C.

BMC Musculoskelet Disord. 2019 Feb 11;20(1):72. doi: 10.1186/s12891-018-2330-1. No abstract available.

23.

Interleukin-6 Receptor Signaling and Abdominal Aortic Aneurysm Growth Rates.

Paige E, Clément M, Lareyre F, Sweeting M, Raffort J, Grenier C, Finigan A, Harrison J, Peters JE, Sun BB, Butterworth AS, Harrison SC, Bown MJ, Lindholt JS, Badger SA, Kullo IJ, Powell J, Norman PE, Scott DJA, Bailey MA, Rose-John S, Danesh J, Freitag DF, Paul DS, Mallat Z.

Circ Genom Precis Med. 2019 Feb;12(2):e002413. doi: 10.1161/CIRCGEN.118.002413.

24.

Impaired mechanical, heat, and cold nociception in a murine model of genetic TACE/ADAM17 knockdown.

Quarta S, Mitrić M, Kalpachidou T, Mair N, Schiefermeier-Mach N, Andratsch M, Qi Y, Langeslag M, Malsch P, Rose-John S, Kress M.

FASEB J. 2019 Mar;33(3):4418-4431. doi: 10.1096/fj.201801901R. Epub 2018 Dec 26.

25.

Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage.

Prenissl N, Lokau J, Rose-John S, Haybaeck J, Garbers C.

Cytokine. 2019 Feb;114:1-5. doi: 10.1016/j.cyto.2018.11.023. Epub 2018 Dec 14.

26.

Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival.

Kleinegger F, Hofer E, Wodlej C, Golob-Schwarzl N, Birkl-Toeglhofer AM, Stallinger A, Petzold J, Orlova A, Krassnig S, Reihs R, Niedrist T, Mangge H, Park YN, Thalhammer M, Aigelsreiter A, Lax S, Garbers C, Fickert P, Rose-John S, Moriggl R, Rinner B, Haybaeck J.

Biochim Biophys Acta Mol Basis Dis. 2019 Feb 1;1865(2):308-321. doi: 10.1016/j.bbadis.2018.11.006. Epub 2018 Nov 9.

27.

Structural and Functional Analyses of the Shedding Protease ADAM17 in HoxB8-Immortalized Macrophages and Dendritic-like Cells.

Cabron AS, El Azzouzi K, Boss M, Arnold P, Schwarz J, Rosas M, Dobert JP, Pavlenko E, Schumacher N, Renné T, Taylor PR, Linder S, Rose-John S, Zunke F.

J Immunol. 2018 Nov 15;201(10):3106-3118. doi: 10.4049/jimmunol.1701556. Epub 2018 Oct 24.

28.

Correction: The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth.

Nivarthi H, Gordziel C, Themanns M, Kramer N, Eberl M, Rabe B, Schlederer M, Rose-John S, Knösel T, Kenner L, Freund P, Aberger F, Han X, Kralovics R, Dolznig H, Jennek S, Friedrich K, Moriggl R.

Oncotarget. 2018 Sep 18;9(73):33865. doi: 10.18632/oncotarget.26156. eCollection 2018 Sep 18.

29.

Thirty-eight-negative kinase 1 mediates trauma-induced intestinal injury and multi-organ failure.

Armacki M, Trugenberger AK, Ellwanger AK, Eiseler T, Schwerdt C, Bettac L, Langgartner D, Azoitei N, Halbgebauer R, Groß R, Barth T, Lechel A, Walter BM, Kraus JM, Wiegreffe C, Grimm J, Scheffold A, Schneider MR, Peuker K, Zeißig S, Britsch S, Rose-John S, Vettorazzi S, Wolf E, Tannapfel A, Steinestel K, Reber SO, Walther P, Kestler HA, Radermacher P, Barth TF, Huber-Lang M, Kleger A, Seufferlein T.

J Clin Invest. 2018 Nov 1;128(11):5056-5072. doi: 10.1172/JCI97912. Epub 2018 Oct 15.

30.

Laboratory diagnostics of murine blood for detection of mouse cytomegalovirus (MCMV)-induced hepatitis.

Stahl FR, Jung R, Jazbutyte V, Ostermann E, Tödter S, Brixel R, Kemmer A, Halle S, Rose-John S, Messerle M, Arck PC, Brune W, Renné T.

Sci Rep. 2018 Oct 4;8(1):14823. doi: 10.1038/s41598-018-33167-7.

31.

Mutations in Craniosynostosis Patients Cause Defective Interleukin-11 Receptor Maturation and Drive Craniosynostosis-like Disease in Mice.

Agthe M, Brügge J, Garbers Y, Wandel M, Kespohl B, Arnold P, Flynn CM, Lokau J, Aparicio-Siegmund S, Bretscher C, Rose-John S, Waetzig GH, Putoczki T, Grötzinger J, Garbers C.

Cell Rep. 2018 Oct 2;25(1):10-18.e5. doi: 10.1016/j.celrep.2018.09.005.

32.

Epithelial RNase H2 Maintains Genome Integrity and Prevents Intestinal Tumorigenesis in Mice.

Aden K, Bartsch K, Dahl J, Reijns MAM, Esser D, Sheibani-Tezerji R, Sinha A, Wottawa F, Ito G, Mishra N, Knittler K, Burkholder A, Welz L, van Es J, Tran F, Lipinski S, Kakavand N, Boeger C, Lucius R, von Schoenfels W, Schafmayer C, Lenk L, Chalaris A, Clevers H, Röcken C, Kaleta C, Rose-John S, Schreiber S, Kunkel T, Rabe B, Rosenstiel P.

Gastroenterology. 2019 Jan;156(1):145-159.e19. doi: 10.1053/j.gastro.2018.09.047. Epub 2018 Sep 28.

33.

Control of Listeria monocytogenes infection requires classical IL-6 signaling in myeloid cells.

Lücke K, Yan I, Krohn S, Volmari A, Klinge S, Schmid J, Schumacher V, Steinmetz OM, Rose-John S, Mittrücker HW.

PLoS One. 2018 Aug 31;13(8):e0203395. doi: 10.1371/journal.pone.0203395. eCollection 2018.

34.

Interleukin 6 trans-signalling and risk of future cardiovascular events.

Ziegler L, Gajulapuri A, Frumento P, Bonomi A, Wallén H, de Faire U, Rose-John S, Gigante B.

Cardiovasc Res. 2019 Jan 1;115(1):213-221. doi: 10.1093/cvr/cvy191.

PMID:
30052808
35.

Differing Outcome of Experimental Autoimmune Encephalitis in Macrophage/Neutrophil- and T Cell-Specific gp130-Deficient Mice.

Holz K, Prinz M, Brendecke SM, Hölscher A, Deng F, Mitrücker HW, Rose-John S, Hölscher C.

Front Immunol. 2018 May 2;9:836. doi: 10.3389/fimmu.2018.00836. eCollection 2018.

36.

Interleukin-6: designing specific therapeutics for a complex cytokine.

Garbers C, Heink S, Korn T, Rose-John S.

Nat Rev Drug Discov. 2018 Jun;17(6):395-412. doi: 10.1038/nrd.2018.45. Epub 2018 May 4. Review.

PMID:
29725131
37.

The enhanced susceptibility of ADAM-17 hypomorphic mice to DSS-induced colitis is not ameliorated by loss of RIPK3, revealing an unexpected function of ADAM-17 in necroptosis.

Fuchslocher Chico J, Falk-Paulsen M, Luzius A, Saggau C, Ruder B, Bolik J, Schmidt-Arras D, Linkermann A, Becker C, Rosenstiel P, Rose-John S, Adam D.

Oncotarget. 2018 Feb 5;9(16):12941-12958. doi: 10.18632/oncotarget.24410. eCollection 2018 Feb 27.

38.

Pharmacological inhibition of IL-6 trans-signaling improves compromised fracture healing after severe trauma.

Kaiser K, Prystaz K, Vikman A, Haffner-Luntzer M, Bergdolt S, Strauss G, Waetzig GH, Rose-John S, Ignatius A.

Naunyn Schmiedebergs Arch Pharmacol. 2018 May;391(5):523-536. doi: 10.1007/s00210-018-1483-7. Epub 2018 Mar 1.

39.

ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling.

Schmidt S, Schumacher N, Schwarz J, Tangermann S, Kenner L, Schlederer M, Sibilia M, Linder M, Altendorf-Hofmann A, Knösel T, Gruber ES, Oberhuber G, Bolik J, Rehman A, Sinha A, Lokau J, Arnold P, Cabron AS, Zunke F, Becker-Pauly C, Preaudet A, Nguyen P, Huynh J, Afshar-Sterle S, Chand AL, Westermann J, Dempsey PJ, Garbers C, Schmidt-Arras D, Rosenstiel P, Putoczki T, Ernst M, Rose-John S.

J Exp Med. 2018 Apr 2;215(4):1205-1225. doi: 10.1084/jem.20171696. Epub 2018 Feb 22.

40.

BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host disease.

Ullrich E, Abendroth B, Rothamer J, Huber C, Büttner-Herold M, Buchele V, Vogler T, Longerich T, Zundler S, Völkl S, Beilhack A, Rose-John S, Wirtz S, Weber GF, Ghimire S, Kreutz M, Holler E, Mackensen A, Neurath MF, Hildner K.

J Clin Invest. 2018 Mar 1;128(3):916-930. doi: 10.1172/JCI89242. Epub 2018 Jan 29.

41.

Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer.

Garbers C, Rose-John S.

Methods Mol Biol. 2018;1725:127-140. doi: 10.1007/978-1-4939-7568-6_11.

PMID:
29322414
42.

The ADAM17 Metalloproteinase Maintains Arterial Elasticity.

Nicolaou A, Northoff BH, Zhao Z, Kohlmaier A, Sass K, Rose-John S, Steffens S, Weber C, Teupser D, Holdt LM.

Thromb Haemost. 2018 Jan;118(1):210-213. doi: 10.1160/TH17-07-0494. Epub 2018 Jan 5. No abstract available.

PMID:
29304540
43.

The hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma.

Lenk L, Pein M, Will O, Gomez B, Viol F, Hauser C, Egberts JH, Gundlach JP, Helm O, Tiwari S, Weiskirchen R, Rose-John S, Röcken C, Mikulits W, Wenzel P, Schneider G, Saur D, Schäfer H, Sebens S.

Oncoimmunology. 2017 Oct 26;7(1):e1368603. doi: 10.1080/2162402X.2017.1368603. eCollection 2017.

44.

Suppressor of Cytokine Signaling 3 in Macrophages Prevents Exacerbated Interleukin-6-Dependent Arginase-1 Activity and Early Permissiveness to Experimental Tuberculosis.

Schmok E, Abad Dar M, Behrends J, Erdmann H, Rückerl D, Endermann T, Heitmann L, Hessmann M, Yoshimura A, Rose-John S, Scheller J, Schaible UE, Ehlers S, Lang R, Hölscher C.

Front Immunol. 2017 Nov 10;8:1537. doi: 10.3389/fimmu.2017.01537. eCollection 2017.

45.

Mucus Detachment by Host Metalloprotease Meprin β Requires Shedding of Its Inactive Pro-form, which Is Abrogated by the Pathogenic Protease RgpB.

Wichert R, Ermund A, Schmidt S, Schweinlin M, Ksiazek M, Arnold P, Knittler K, Wilkens F, Potempa B, Rabe B, Stirnberg M, Lucius R, Bartsch JW, Nikolaus S, Falk-Paulsen M, Rosenstiel P, Metzger M, Rose-John S, Potempa J, Hansson GC, Dempsey PJ, Becker-Pauly C.

Cell Rep. 2017 Nov 21;21(8):2090-2103. doi: 10.1016/j.celrep.2017.10.087.

46.

A new multiple trauma model of the mouse.

Fitschen-Oestern S, Lippross S, Klueter T, Weuster M, Varoga D, Tohidnezhad M, Pufe T, Rose-John S, Andruszkow H, Hildebrand F, Steubesand N, Seekamp A, Neunaber C.

BMC Musculoskelet Disord. 2017 Nov 21;18(1):468. doi: 10.1186/s12891-017-1813-9. Erratum in: BMC Musculoskelet Disord. 2019 Feb 11;20(1):72.

47.

Distinct Effects of IL-6 Classic and Trans-Signaling in Bone Fracture Healing.

Prystaz K, Kaiser K, Kovtun A, Haffner-Luntzer M, Fischer V, Rapp AE, Liedert A, Strauss G, Waetzig GH, Rose-John S, Ignatius A.

Am J Pathol. 2018 Feb;188(2):474-490. doi: 10.1016/j.ajpath.2017.10.011. Epub 2017 Nov 13.

48.

Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib.

Sobotta S, Raue A, Huang X, Vanlier J, Jünger A, Bohl S, Albrecht U, Hahnel MJ, Wolf S, Mueller NS, D'Alessandro LA, Mueller-Bohl S, Boehm ME, Lucarelli P, Bonefas S, Damm G, Seehofer D, Lehmann WD, Rose-John S, van der Hoeven F, Gretz N, Theis FJ, Ehlting C, Bode JG, Timmer J, Schilling M, Klingmüller U.

Front Physiol. 2017 Oct 9;8:775. doi: 10.3389/fphys.2017.00775. eCollection 2017.

49.

Factor XII-Driven Inflammatory Reactions with Implications for Anaphylaxis.

Bender L, Weidmann H, Rose-John S, Renné T, Long AT.

Front Immunol. 2017 Sep 15;8:1115. doi: 10.3389/fimmu.2017.01115. eCollection 2017. Review.

50.

Cancer-associated mutations in the canonical cleavage site do not influence CD99 shedding by the metalloprotease meprin β but alter cell migration in vitro.

Bedau T, Schumacher N, Peters F, Prox J, Arnold P, Koudelka T, Helm O, Schmidt F, Rabe B, Jentzsch M, Rosenstiel P, Sebens S, Tholey A, Rose-John S, Becker-Pauly C.

Oncotarget. 2017 Jul 4;8(33):54873-54888. doi: 10.18632/oncotarget.18966. eCollection 2017 Aug 15.

Supplemental Content

Loading ...
Support Center